Keurig Dr Pepper Inc. KDP will launch its fourth-quarter monetary outcomes, earlier than the opening bell, on Tuesday, Feb. 25, 2025.
Analysts count on the Burlington, Massachusetts-based firm to report quarterly earnings at 57 cents per share, up from 55 cents per share within the year-ago interval. Keurig Dr Pepper initiatives quarterly income of $4 billion, in comparison with $3.87 billion a yr earlier, in keeping with knowledge from Benzinga Professional.
On Oct. 29, 2024, Keurig Dr Pepper introduced the pricing of a secondary providing of frequent inventory by JAB at $32.85 per share.
Keurig Dr Pepper shares gained 0.2% to shut at $34.12 on Monday.
Benzinga readers can entry the most recent analyst scores on the Analyst Inventory Rankings web page. Readers can kind by inventory ticker, firm title, analyst agency, score change or different variables.
Let’s take a look at how Benzinga’s most-accurate analysts have rated the corporate within the latest interval.
- Barclays analyst Lauren Lieberman maintained an Chubby score and lower the value goal from $39 to $36 on Jan. 17, 2025. This analyst has an accuracy fee of 60%.
- UBS analyst Sean King maintained a Purchase score and lower the value goal from $42 to $37 on Jan. 16, 2025. This analyst has an accuracy fee of 66%.
- Wells Fargo analyst Chris Carey maintained an Chubby score and lower the value goal from $42 to $40 on Jan. 7, 2025. This analyst has an accuracy fee of 61%.
- Piper Sandler analyst Mike Lavery initiated protection on the inventory with a Impartial score and a value goal of $35 on Jan. 7, 2025. This analyst has an accuracy fee of 64%.
- Deutsche Financial institution analyst Steve Powers upgraded the inventory from Maintain to Purchase and raised the value goal from $37 to $39 on Dec. 12, 2024. This analyst has an accuracy fee of 67%.
Contemplating shopping for KDP inventory? Right here’s what analysts assume:
Learn This Subsequent:
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
